title: The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
abstract: Over the past decade (18)F-fluorodeoxyglucose (FDG)-PET combined with computed tomography has gained a central role in the management of patients with lymphoma. The use of FDG-PET for staging and assessing treatment response in Hodgkin's and 'aggressive' non-Hodgkin's lymphoma is now well established, and the prognostic impact of the response to treatment assessed by FDG-PET is being increasingly recognized. Despite the widespread utilization of FDG-PET in clinical practice, key questions remain on its optimal use in certain contexts. One such area that is generating intense interest is the role of interim FDG-PET (typically performed after two to four cycles of chemotherapy) to guide treatment strategies. The author's will review the current available evidence in this area, highlighting questions in need of further study.
authors.affiliation: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk
authors.forename: Shamzah
authors.initials: S
authors.lastname: Araf
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
mesh_terms: D002986:Clinical Trials as Topic; D019788:Fluorodeoxyglucose F18 / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18